▎ 摘　　要

NOVELTY - Composition (C1) comprises one or more antibodies non-covalently conjugated to graphene oxide. USE - The composition is pharmaceutical composition useful for treating cancer in a patient, preferably human patient. The cancer is primary, secondary, refractory, or relapsing tumor. The primary, secondary, refractory, or relapsing tumor is blood cell tumor, sarcoma or carcinoma. The blood cell tumor is lymphoma. The lymphoma is a non-Hodgkin's lymphoma. The non-Hodgkin's lymphoma is follicular lymphoma, mantle cell lymphoma, marginal zone cell lymphoma, diffuse large-B-cell lymphoma or Burkitt lymphoma. The sarcoma is osteosarcoma. The carcinoma is pancreatic, preferably pancreatic adenocarcinoma. The cancer is associated with expression of CD20 (all claimed). The composition is also used for treating autoimmune disorders and preventing graft rejection. ADVANTAGE - The composition has excellent stability. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following: (1) method (M1) for treating cancer, involves (a) identifying a patient, (b) administering the composition (C1) to the patient and (c) carrier; (2) composition (C2) for delivery of one or more antibodies to a cell, comprising (a) graphene oxide, and (b) one or more antibodies non-covalently bound to the graphene oxide, where the non-covalent binding induces a conformational change in graphene oxide; (3) cell comprising the composition (C1); (4) kit comprising graphene oxide and one or more antibodies, where the graphene oxide is non-covalently bound to one or more antibodies, and instructions for using the composition; (5) method (M2) for preparing nanomaterial complex for delivery of several antibodies to a cell, involves (a) preparing the nanomaterial through a functionalization process, where the nanomaterial is a graphene oxide sheet, (b) attaching several antibody monomers to the graphene oxide sheet, where the loading is through non-covalent binding, (c) incubating the antibody monomers with the graphene oxide sheet in a low salt solution, and (d) forming a stable aqueous dispersion of the nanomaterial complex; (6) method (M3) for delivering one or more antibodies to a cell comprising composition, involves contacting the cell with the composition for enough time to permit cross-linking of the antibody to the cell; and (7) molecular probe comprising the composition (C1), and further comprising a detectable label.